With the World Drug Safety Congress Americas coming up next month, we decided to take a look at the speakers from the Global Drug Safety Setting stream on day one. We've got some great talks lined up from some of the best names in the industry. Don't miss your chance to hear from:
Dr. Beninger is Vice President of Global Patient Safety at Genzyme, a Sanofi Company in Cambridge, Massachusetts, where he is responsible for maintaining the global safety profile of the company's cardio-renal and biosurgical device products. He began his career in drug development in 1987 at the U.S. Food and Drug Administration, and then at Merck & Company before joining Genzyme in 2006. Dr. Beninger is trained in internal medicine and infectious diseases. He received his MD from University of California, Davis, his BA from Claremont McKenna College in Claremont, California, and his MBA from St Joseph's University in Philadelphia, Pennsylvania. He has published and spoken extensively on regulatory medicine and product safety, and he is a fellow of the American College of Physicians and the Infectious Disease Society of America.
Ronald W. Leong, MD, Executive Director, US Patient Safety, AstraZeneca, has 24 years of experience in the pharmaceutical industry. He has worked at Upjohn, Proctor & Gamble, Wyeth and AstraZeneca, where he has been employed since 2002. His experience includes Clinical Development, U.S. regulatory affairs and both U.S. and international Drug Safety. Dr. Leong represents AstraZeneca on PhRMA and BIO working groups relating to Pharmacovigilance. He earned his A.B. and M.D. degrees at Washington University of St. Louis, U.S. and completed a residency in Internal Medicine. Dr. Leong is board certified in Internal Medicine and practiced medicine prior to entering the pharmaceutical industry.
Rudi Scheerlinck is a certified GP (VUB, Brussels) who holds a Post-graduate Program in Pharmacology and Pharmaceutical Medicine (ULB, Brussels). During 14 years of pharmacovigilance experience, he has gained experience in a broad area of interests, including signal detection, medical analysis, interpretation of safety and epidemiological data, management of safety issues, people management, and general management. He has set up and led medico-scientific teams covering a variety of medicinal products (small molecules, antibodies, and vaccines) across several therapeutic areas (pre- and post-marketing). He acquired experience in developing and maintaining a pharmacovigilance system with close contacts with QA, IT, and Epidemiology. At UCB he occupied positions including Deputy EU QPPV, Head Medical Evaluation, and Director in a Safety Evaluation and Risk Management group. In between, he was Head of Safety Evaluation and Risk Management for the pediatric vaccines at GSK Biologicals. Currently he is working within Integrated Medical Safety at Novartis Oncology.
Steven Du has over 10 years of clinical research and global pharmacovigilance and pharmacoepidemiology experience. He's currently Senior Director of Pharmacoviglance and Pharmacoepidemiology at AMAG Pharmaceuticals, overseeing all aspects of pre and post-marketing global drug safety and risk management. Prior to joining AMAG, Steven was Associate Director and Head of Pharmacovigilance at KV Pharmaceuticals in St. Louis. Steven also worked at Valeant Pharmaceuticals International in Los Angeles as Medical Officer, Pharmacovigilance and University of Southern California as Epidemiologist. He is an Editorial Board member of European Journal of Cancer Care and Life member of Association of International Union Against Cancers Fellows. Steven earned his M.D. at Beijing Medical University, PhD in epidemiology at National University of Singapore and MBA at University of Southern California.
And many more! Visit the website for full programme information.